Medical Cyclotron Market: Global Growth, India Opportunity & Future Outlook
The medical cyclotron market is heating up as PET/CT and radiopharmaceutical demand surge worldwide—but can India build enough local isotope-production capacity to keep pace?
The global medical cyclotron market was worth USD 265.4 million (₹2,533 crore) in 2025and is expected to reach USD 493.8 million (₹4,712 crore) by 2034, expanding at a CAGR of 6.93%, according to IMARC Group. Growth is being driven by rising PET/CT adoption, increasing demand for medical radioisotopes, the expanding cancer burden and investment in radiopharmaceutical infrastructure.
Global Medical Cyclotron Market Growth: PET Imaging and Radiopharmaceutical Demand
Rising Oncology & PET Demand: Increasing cancer incidence and wider use of PET/CT imaging for cancer diagnosis, staging and treatment planning are driving demand for medical cyclotrons and the short-lived radionuclides they produce. Fluorine-18 remains particularly important for FDG-PET, with a half-life of approximately 110 minutes.
Medical Cyclotron Energy Segment: The 16–18 MeV segment accounted for 56% of the medical cyclotron market in 2025, according to IMARC, reflecting strong demand for routine PET isotope production. Higher-energy and more flexible systems are also attracting attention as radiopharmaceutical applications diversify.
North America and Asia-Pacific Market Growth: North America remains the largest regional market, while Asia-Pacific is among the fastest-growing markets, supported by healthcare modernization, expanding PET/CT networks and increasing investment in nuclear-medicine infrastructure.
Integrated Cyclotron-Radiopharmacy Facilities: Market growth is increasingly connected to integrated cyclotron and radiopharmacy infrastructure, allowing healthcare institutions and regional networks to produce, process and distribute medical radioisotopes closer to clinical demand.
Medical Cyclotron Market in India: PET/CT Expansion Creates New Demand
Growing Cancer-Care Demand: India's increasing cancer burden is driving demand for advanced molecular imaging and PET/CT services, creating a parallel need for dependable radiopharmaceutical supply.
Rapid PET/CT Infrastructure Growth: PET/CT installations in India have grown dramatically from fewer than 20 units in the mid-2000s to over 430–500 operational scanners nationwide. The private sector drives more than 55% of these new installations, with setup costs averaging between Rs. 7 Crore and Rs. 11 Crore per facility.
Need for Regional Radioisotope Production: Short-lived radionuclides such as F-18 create logistical challenges when transported over long distances. Regional medical cyclotrons and radiopharmacies can bring isotope production closer to PET/CT centres and help reduce transportation-related decay.
Emerging Tier-2 and Tier-3 Opportunities: As advanced cancer-care infrastructure expands beyond India's largest cities, strategically located cyclotron and radiopharmacy hubs could help extend access to PET-based nuclear medicine.
Major Medical Cyclotron Investment: In 2026, Maharashtra approved a ₹300-crore High-Energy Medical Cyclotron Project in Nagpur, planned around a 30 MeV cyclotron, highlighting the growing focus on regional medical-isotope production.
Medical Cyclotron Project Challenges: Cost, Regulation and Skilled Workforce
High Medical Cyclotron Infrastructure Costs: A complete project involves considerably more than the accelerator. Investment can include the cyclotron, shielded bunker, target systems, hot cells, radiochemistry laboratories, synthesis modules, HVAC, utilities and quality-control infrastructure.
Specialised Nuclear Medicine Workforce: Successful operations require cyclotron operators, radiochemists, medical physicists, nuclear-medicine specialists and radiation-safety professionals. Access to specialised talent remains an important consideration when planning a new facility.
AERB and Radiation Safety Compliance: In India, medical cyclotron projects must address applicable AERB approval for cyclotron, radiation protection, facility design, radioactive-material handling, quality assurance and licensing. Integrating regulatory planning early can help avoid delays during project execution.
Radiopharmaceutical Supply Chain: Cyclotron capacity must be matched to PET/CT volumes, isotope requirements, production schedules and distribution radius. Building excess capacity without sufficient clinical demand can affect project economics.
Future of Medical Cyclotron Technology: Theranostics and Multi-Isotope Production
Beyond FDG-PET: The future of nuclear medicine extends beyond conventional FDG. New molecular imaging agents and theranostic applications are increasing interest in a wider range of medical radionuclides.
Flexible Isotope Production: Healthcare institutions may increasingly favour cyclotron systems capable of supporting multiple radionuclides and evolving radiopharmaceutical applications, rather than infrastructure designed for a single isotope.
Automation and Digitalisation: Automated radiochemistry, advanced target systems, remote monitoring and digital workflow technologies could improve production efficiency, quality control and operational consistency.
Global CanCare: Integrated Medical Cyclotron and Radiopharmacy Solutions
A medical cyclotron is not a standalone piece of equipment. It sits at the centre of a wider ecosystem connecting isotope production, radiopharmacy, radiation shielding, PET/CT, quality control, regulatory compliance and clinical delivery.
This is where Global CanCare brings an integrated approach to healthcare infrastructure.
Global CanCare connects healthcare institutions with cyclotron and radiopharmacy capabilities, radiation shielding solutions, medical technologies and specialised project expertise to support the development of modern nuclear-medicine facilities.
From understanding clinical requirements and evaluating technology options to planning radiopharmacy infrastructure, radiation shielding and supporting facility requirements, an integrated approach can help create a more efficient and future-ready project.
Build a Future-Ready Nuclear Medicine Facility with Global CanCare
As PET/CT adoption, radiopharmaceutical demand and precision oncology continue to grow, reliable isotope-production infrastructure will become increasingly important.
For hospitals, diagnostic networks and healthcare investors, the opportunity is not simply to purchase a cyclotron. It is to develop a complete, scalable nuclear-medicine ecosystem that can support current PET demand while adapting to future radiopharmaceutical and theranostic applications.
Planning a Medical Cyclotron or Radiopharmacy Facility?
Global CanCare can help you plan the complete ecosystem—from cyclotron technology and radiopharmacy to radiation shielding and integrated cancer-care infrastructure.
Talk to Global CanCare to explore the right technology and infrastructure strategy for your next nuclear-medicine project.
Connect with Our India Team
Northern Region — Delhi
+91 8120115666
Western Region — Mumbai
+91 9098793898
Southern & Eastern Region — Bangalore / Kolkata
+91 7974667979
General Enquiries
info@globalcancare.com
References / Sources
Atomic Energy Regulatory Board (AERB) — Medical Cyclotron regulatory requirements and guidelines.
Atomic Energy Regulatory Board (AERB) — Medical Cyclotron Facilities, AERB/RF-RS/SG-3, 2016.
Kim M.J., Kim H.I., Kwon J., Kim K.P. — Current Trends in Cyclotrons and Radionuclide Production: A Comprehensive Analysis in the Republic of Korea, Nuclear Engineering and Technology, 2025.
The Hindu — Maharashtra Govt to set up medical cyclotron project in Nagpur to elevate cancer research, June 17, 2026.
Rangarajan V., Purandare N.C., Sharma A.R., Shah S. — PET/CT: Current Status in India, Indian Journal of Radiology & Imaging, 2008.
Tsurusaki M. et al. — Clinical Application of 18F-Fluorodeoxyglucose Positron Emission Tomography for Assessment and Evaluation After Therapy for Malignant Hepatic Tumor, Journal of Gastroenterology, 2013.
Ministry of Health & Family Welfare / Press Information Bureau (Government of India) — Towards a Cancer-Free India, 2025.
IMARC Group — Medical Cyclotron Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast.
IAEA (International Atomic Energy Agency) — Resources and guidance on cyclotrons, medical radioisotopes and radiopharmaceutical production.